Flmodafinil

Flmodafinil (CRL-40,940; NLS-4; lauflumide; bisfluoromodafinil; JBG01-41) is a synthetic eugeroic of the diphenylmethyl sulfinyl acetamide structural class, bearing two para-fluorine substituents on the phenyl rings of the modafinil scaffold. First synthesized and patented by Laboratoire L. Lafon in France in the mid-1980s as part of a systematic structure-activity exploration of modafinil derivatives, the compound remained largely uninvestigated for approximately two decades until NLS Pharmaceutics AG (formerly NLS Pharmaceuticals) acquired development rights and advanced it into preclinical programs for narcolepsy, attention deficit hyperactivity disorder, Alzheimer’s disease, idiopathic hypersomnia, and chronic fatigue syndrome. The compound acts as a selective atypical dopamine reuptake inhibitor with a binding affinity (Ki) of 4,090 nM at the dopamine transporter, approximately 12-fold selectivity over the serotonin transporter (Ki 48,700 nM), and negligible affinity for the sigma-1 receptor (Ki greater than 100,000 nM). In functional assays, flmodafinil blocks the dopamine transporter by approximately 83 percent, exceeding the inhibition produced by methylphenidate without concurrent adrenergic effects. Both the (S)-(+) enantiomer (JBG1-048, Ki 2,970 nM) and the (R)-(-) enantiomer (JBG1-049, Ki 4,830 nM) elevate extracellular dopamine in the rat nucleus accumbens to 150 to 200 percent of baseline at the highest assessed doses, with the (R)-(-) enantiomer producing a notably slower onset and longer duration of dopaminergic effect compared to (R)-modafinil. In the principal comparative preclinical study (Luca et al. 2018), NLS-4 at 64 mg/kg intraperitoneally in C57BL/6J mice induced approximately 151 minutes of additional wakefulness compared to approximately 110 minutes for modafinil at 150 mg/kg, a 2.3-fold higher dose, establishing that flmodafinil possesses substantially greater wake-promoting potency per milligram than the parent compound. Recovery sleep following NLS-4-induced wakefulness was characterized by less non-rapid eye movement (NREM) sleep amount and attenuated delta power elevation compared to modafinil-treated animals, suggesting a qualitatively different and possibly more favorable recovery profile with reduced homeostatic sleep pressure accumulation despite longer drug-induced wakefulness. A subsequent preclinical study in a rat model of chronic severe fatigue (Konofal et al. 2023) reported that NLS-4 at 16 mg/kg produced locomotor activity restoration comparable to modafinil at 64 mg/kg, confirming a four-fold potency advantage with more sustained effects on circadian activity patterns. Unlike modafinil, flmodafinil does not induce cytochrome P450 CYP3A4 or CYP3A5 enzymes in human hepatocyte cultures, a pharmacologically significant distinction that reduces the potential for drug-drug interactions in chronic dosing regimens. The compound has not been approved for medical use in any jurisdiction. Clinical development programs initiated by NLS Pharmaceutics for narcolepsy, ADHD, and Alzheimer’s disease have been discontinued without publication of human trial data; preclinical development for chronic fatigue syndrome remains the only active program as of the most recent public disclosure. No published human clinical trial data exist for flmodafinil. The World Anti-Doping Agency has initiated investigations into urinary metabolism and detection methods for flmodafinil and its structural relative fladrafinil (CRL-40,941), confirming regulatory awareness of the compound in the context of competitive sport. This monograph reviews the chemistry, synthesis, and stereochemistry of flmodafinil; the dopamine transporter pharmacology and enantiomer-resolved binding data; the preclinical wake-promoting and chronic fatigue evidence; the pharmacokinetic profile as characterized in animal models; sourcing and quality verification considerations for laboratory work; and a comparative assessment of five eugeroic and wakefulness-promoting alternatives against flmodafinil on five competency standards. The compound is supplied exclusively as a research-grade preparation; investigators should obtain analytical confirmation of identity, purity, and enantiomeric composition on every lot.